Immunic
IMUX
58 hedge funds and large institutions have $81.3M invested in Immunic in 2018 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 15 reducing their positions, and 12 closing their positions.
24% more capital invested
Capital invested by funds: $65.6M → $81.3M (+$15.7M)
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
2% more funds holding
Funds holding: 57 → 58 (+1)
7% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 15
0.01% more ownership
Funds ownership: 0.07% → 0.07% (+0.01%)
86% less call options, than puts
Call options by funds: $114K | Put options by funds: $830K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.22M |
| 2 |
Millennium Management
New York
|
+$941K |
| 3 |
Goldman Sachs
New York
|
+$893K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$757K |
| 5 |
AG
Artal Group
Luxembourg
|
+$716K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$1.21M |
| 2 |
William Blair & Company
Chicago,
Illinois
|
-$592K |
| 3 |
JP Morgan Chase
New York
|
-$383K |
| 4 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
-$376K |
| 5 |
Renaissance Technologies
New York
|
-$266K |
IMUX Hedge Fund Activity: Q1 2018 in Review
58 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q1 2018, worth a combined $81.3M — up 24% from $65.6M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new IMUX positions and 12 closed out — a net gain of 2 holders — while 16 added to existing stakes and 15 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $3.22M. The largest seller was Granahan Investment Management, cutting an estimated $1.21M.
- 58 institutional investors held Immunic (IMUX) as of Q1 2018, up from 57 in Q4 2017.
- Funds reported $81.3M of Immunic stock for Q1 2018, up 24% quarter-over-quarter.
- 14 funds opened new Immunic positions in Q1 2018 and 12 closed out, a net change of +2 holders.
- The largest Immunic buyer in Q1 2018 was T. Rowe Price Associates, an estimated $3.22M added.
- The largest Immunic seller in Q1 2018 was Granahan Investment Management, an estimated $1.21M sold.
Based on aggregated 13F filings for Q1 2018.